Search

Your search keyword '"Pivot, Xavier"' showing total 987 results

Search Constraints

Start Over You searched for: Author "Pivot, Xavier" Remove constraint Author: "Pivot, Xavier"
987 results on '"Pivot, Xavier"'

Search Results

154. Ki67 Assessment by qRT-PCR in OncotypeDx ® Breast Recurrent Score®: Low Correlation With IHC Assessment of ki67 and Prognostic Impact of ki67 RNA Level of Expression.

155. Tumeurs rares du sein

161. Evolution of Physical Status From Diagnosis to the End of First-Line Treatment in Breast, Lung, and Colorectal Cancer Patients: The PROTECT-01 Cohort Study Protocol

162. Assessment of quality and clinical similarity (pharmacokinetic and safety) of HD204, a biosimilar of bevacizumab.

163. Four-year follow-up of a phase III study comparing SB3 (trastuzumab biosimilar) and reference trastuzumab in HER2-positive early or locally advanced breast cancer in neoadjuvant setting.

164. MONARCH 2: Subgroup analysis of patients receiving abemaciclib + fulvestrant as first- and second-line therapy for HR+, HER2- advanced breast cancer.

165. Establishing analytical and clinical similarity between HD201 and herceptin.

166. International network of cancer genome projects

167. A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: design of the CARDAPAC study

172. Additional file 1 of Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries

173. Additional file 3 of Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries

174. Additional file 6 of Real-world patient-reported outcomes of women receiving initial endocrine-based therapy for HR+/HER2− advanced breast cancer in five European countries

177. 6 months versus 12 months of adjuvant trastuzumab in early breast cancer (PHARE): final analysis of a multicentre, open-label, phase 3 randomised trial

179. Pan-cancer analysis of whole genomes

182. Cisplatin in Combination With Either Gemcitabine or Irinotecan in Carcinomas of Unknown Primary Site: Results of a Randomized Phase II Study—Trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01)

183. Additional file 1: of Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine Âą pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

184. Additional file 2: of Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine Âą pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

186. Abstract PD5-11: Association of immune gene expression with outcome in the MARIANNE phase 3 clinical trial in HER2-positive metastatic breast cancer (MBC)

187. Abstract P3-08-01: MONARCH 2: Interim analysis of overall survival in patients with poor prognostic factors

188. Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer

189. The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

191. Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial

194. Trastuzumab emtansine with or without pertuzumab versus trastuzumab with taxane for human epidermal growth factor receptor 2–positive advanced breast cancer: Final results from MARIANNE

195. Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics

196. Relationship between tumor biomarkers and efficacy in MARIANNE, a phase III study of trastuzumab emtansine ± pertuzumab versus trastuzumab plus taxane in HER2-positive advanced breast cancer

197. Prognosis value of a genetic score based on germline genetic variants in a prospective cohort of early triple-negative breast cancer patients.

199. Evaluation of survival by ADCC status: Subgroup analysis of SB3 (Trastuzumab Biosimilar) and reference trastuzumab in patients with HER2-positive early breast cancer at three-year follow-up.

Catalog

Books, media, physical & digital resources